Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer

Oncogene

Volumn 31, Issue 15, 2012, Pages 1988-1994

  Taniguchi, H ^a,b   Jacinto, F V ^a,c   Villanueva, A ^a   Fernandez, A F ^a   Yamamoto, H ^b   Carmona, F J ^a   Puertas, S ^a   Marquez, V E ^d   Shinomura, Y ^b   Imai, K ^e   Esteller, M ^a,f,g  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF BARCELONA   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

epigenetics; EZH2; histone methyltransferase; KLF2

Indexed keywords

3 DEAZANEPLANOCIN A; BETA ACTIN; HISTONE H3; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE EZH2; KRUPPEL LIKE FACTOR 2; LYSINE; NUCLEOLIN; POLYCOMB GROUP PROTEIN; PROTEIN P15; PROTEIN P21; PROTEIN P53; RNA POLYMERASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CARCINOGENICITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MORTALITY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN FAMILY; RNA INTERFERENCE; TUMOR XENOGRAFT;

ADENOSINE; ANIMALS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSFECTION;

MUS MUSCULUS;

EID: 84859736577     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.387     Document Type: Article

References (26)

1. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M. (2007).The gene encoding the prostatic tumor suppressor PSP94 is a targetfor repression by the Polycomb group protein EZH2. Oncogene 26:4590-4595. (Pubitemid 47037047)
2. Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P et al.(2005). Inhibition of vascular permeability factor/vascular endothelialgrowth factor-mediated angiogenesis by the Kruppel-like factorKLF2. J Biol Chem 280: 28848-28851. (Pubitemid 41161328)
3. Black AR, Black JD, Azizkhan-Clifford J. (2001). Sp1 and kruppellikefactor family of transcription factors in cell growth regulationand cancer. J Cell Physiol 188: 143-160. (Pubitemid 32622905)
4. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K.(2003). EZH2 is downstream of the pRB-E2F pathway, essential forproliferation and amplified in cancer. EMBO J 22: 5323-5335. (Pubitemid 37279943)
5. Buckley AF, Kuo CT, Leiden JM. (2001). Transcription factor LKLFis sufficient to program T cell quiescence via a c-Myc-dependentpathway. Nat Immunol 2: 698-704. (Pubitemid 32747158)
6. Bureau C, Hanoun N, Torrisani J, Vinel JP, Buscail L, Cordelier P.(2009). Expression and function of Kruppel like-factors (KLF) incarcinogenesis. Curr Genomics 10: 353-360.
7. Chen H, Tu SW, Hsieh JT. (2005). Down-regulation of humanDAB2IP gene expression mediated by polycomb Ezh2 complexand histone deacetylase in prostate cancer. J Biol Chem 280:22437-22444. (Pubitemid 40827899)
8. Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL.(2010). Genomic profiling of tumor initiating prostatospheres.BMC Genomics 11: 324.
9. Fernandez-Zapico ME, Lomberk GA, Tsuji S, Demars CJ, Bardsley MR, Lin YH et al. (2010). Functional family-widescreening of SP/KLF proteins identifies a subset of suppressorsof KRAS-mediated cell growth. Biochem J 435: 529-537.
10. Fujii S, Ito K, Ito Y, Ochiai A. (2008). Enhancer of zeste homologue 2(EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332.
11. Kaczynski J, Cook T, Urrutia R. (2003). Sp1-and Kruppel-liketranscription factors. Genome Biol 4: 206.
12. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N. (2010). Fatty acid binding protein 5 andPPARbeta/delta are critical mediators of epidermal growthfactor receptor-induced carcinoma cell growth. J Biol Chem 285:19106-19115.
13. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al.(2003). EZH2 is a marker of aggressive breast cancer and promotesneoplastic transformation of breast epithelial cells. Proc Natl AcadSci USA 100: 11606-11611. (Pubitemid 37205983)
14. Martin C, Zhang Y. (2005). The diverse functions of histone lysinemethylation. Nat Rev Mol Cell Biol 6: 838-849.
15. Pasini D, Bracken AP, Helin K. (2004). Polycomb group proteins incell cycle progression and cancer. Cell Cycle 3: 396-400. (Pubitemid 40278219)
16. Ringrose L, Paro R. (2004). Epigenetic regulation of cellular memoryby the Polycomb and Trithorax group proteins. Annu Rev Genet 38:413-443. (Pubitemid 40013734)
17. Simon JA, Lange CA. (2008). Roles of the EZH2 histone methyltransferasein cancer epigenetics. Mutat Res 647: 21-29.
18. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. (2007). Pharmacologic disruption of Polycomb-repressive complex2-mediated gene repression selectively induces apoptosis in cancercells. Genes Dev 21: 1050-1063. (Pubitemid 46686474)
19. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. (2004). Stemcells and cancer; the Polycomb connection. Cell 118: 409-418.
20. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. (2002). The polycomb group proteinEZH2 is involved in progression of prostate cancer. Nature 419:624-629.
21. Wang F, Zhu Y, Huang Y, McAvoy S, Johnson WB, Cheung TH et al.(2005). Transcriptional repression of WEE1 by Kruppel-like factor2 is involved in DNA damage-induced apoptosis. Oncogene 24:3875-3885. (Pubitemid 40896399)
22. Wu J, Lingrel JB. (2004). KLF2 inhibits Jurkat T leukemia cell growthvia upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene 23: 8088-8096. (Pubitemid 39531849)
23. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A et al.(2011). Somatic mutations at EZH2 Y641 act dominantly through amechanism of selectively altered PRC2 catalytic activity, to increaseH3K27 trimethylation. Blood 117: 2451-2459.
24. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA et al. (2007).Integrative genomics analysis reveals silencing of beta- adrenergicsignaling by polycomb in prostate cancer. Cancer Cell 12: 419-431. (Pubitemid 350046407)
25. Yu J, Cao Q, Yu J, Wu L, Dallol A, Li J et al. (2010). The neuronalrepellent SLIT2 is a target for repression by EZH2 in prostatecancer. Oncogene 29: 5370-5380.
26. Zhao C, Meng A. (2005). Sp1-like transcription factors are regulatorsof embryonic development in vertebrates. Dev Growth Differ 47:201-211. (Pubitemid 40904920)